drugset / Trial / NCT03523273
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
Phase 2
Completed
136 enrolled
Michael Camilleri, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNovo Nordisk A/S · collab
RandomizedFactorialDouble-blindTreatment
Summary
This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
Timeline
- Start
- 2017-11-29
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 3 mg | Subcutaneous |